Glucoside compound targeting Keap1 as well as preparation method and application thereof

By targeting Keap1 glycoside compounds to regulate Nrf2 and DDX5 and inhibiting ulcerative colitis, the glycoside compounds of the existing Keap1 inhibitors are solved, and significant anti-inflammatory effects and safety are achieved.

CN119039366APending Publication Date: 2024-11-29CHINESE MEDICINE GUANGDONG LABORATORY +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411271440.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-11
Publication Date
2024-11-29

AI Technical Summary

Technical Problem

The existing Keap1 inhibitors have insufficient biological activity, poor binding ability, off-target phenomenon and carcinogenic risk in the treatment of ulcerative colitis, and it is difficult to effectively regulate the Keap1/Nrf2 signaling pathway, resulting in poor efficacy and toxic side effects.

Method used

Develop glycoside compounds targeting Keap1, which binds to Keap1 through specific structural formulas, regulates Nrf2 and DDX5 proteins, inhibits the synthesis of proinflammatory factors, and promotes the production of anti-inflammatory factors, and is used to treat ulcerative colitis.

Benefits of technology

It achieved significant anti-ulcerative colitis efficacy, which was better than the existing drug mesalazine, reduced the expression of inflammatory factors, improved intestinal mucosal damage, and had no obvious toxicity, and was dose-dependent and targeted.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119039366A_ABST
    Figure CN119039366A_ABST
Patent Text Reader

Abstract

The invention discloses a glycoside compound targeting Keap1, the compound has a structural formula (I) imgabs0 # (I), and application of the compound in preparation of a medicine for treating diseases caused by activity abnormity of Kelch-like ECH associated protein 1 (Kelch-like ECH associated protein 1). The compound disclosed by the invention can inhibit the generation of inflammatory factors, effectively improve the weight loss of mice with ulcerative colitis, reduce the disease activity index (DAI) of the mice with ulcerative colitis, and improve the symptoms of diarrhea, hematochezia, weight loss, colorectal stenosis shortening and the like of the mice with ulcerative colitis.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of medicinal chemistry, and in particular to a class of glycoside compounds targeting Keap1, and methods for preparing the same, and applications in the pharmaceutical field, in particular applications for preparing drugs for treating and / or preventing ulcerative colitis. Background Art

[0002] Ulcerative colitis (UC) is a common chronic inflammatory disease of the intestine. It has a complex etiology, is difficult to cure, is prone to relapse, has a poor prognosis, and has a high risk of developing colon cancer. UC is a chronic inflammatory disease whose etiology has not yet been fully clarified. It is mainly manifested by recurrent or persistent chronic inflammatory lesions of the intestinal mucosa. Clinical symptoms include abdominal pain, diarrhea, and bloody stools. As the course of UC increases, it will cause irreversible damage to the intestine, leading to increased surgical and hospitalization rates and an increased risk of cancer. For example, within 5 years after diagnosis, about 20% of UC patients are hospitalized and 7% require colectomy; the combined cumulative risk of colorectal cancer within 20 years of the disease is 4.5% (Jama, 2023, 330, 951–965). UC has a complex etiology, is prone to relapse, has a poor prognosis, and currently has no radical cure. The principle of treatment emphasizes prolonging the maintenance of remission time.

[0003] The pathogenesis of UC is related to abnormalities of colonic epithelial cells, mucus barriers, epithelial barriers, as well as genetic factors and environmental factors. Colonic epithelial damage is a typical feature of UC. The colonic epithelium is composed of absorptive colonocytes and special secretory cells (such as goblet cells, enteroendocrine cells, etc.). Goblet cells can synthesize and secrete the mucus protein Muc2 to form a protective mucus layer to prevent pathogens and toxic substances from reaching and destroying the epithelium. Among them, the PPARγ / SIRT1 / NF-κBp65 signaling pathway can play a role in UC intestinal mucosal destruction. In addition, the Keap1 / Nrf2 signaling pathway also plays an important role in treating intestinal mucosal damage in mice with ulcerative colitis, maintaining the integrity of intestinal epithelial cells, and repairing epithelial cell damage to resist colitis (AnimalScience Journal, 2020, 91, 1–12). The proliferation and differentiation of the intestinal epithelium are regulated by multiple pathways, including Notch, MAPK, Wnt, Hippo and bone morphogenetic protein (BMP) signaling. Intestinal macrophages are the main players in intestinal immune homeostasis and intestinal inflammation. In patients with UC, intestinal inflammation is closely related to the imbalance of intestinal M1 / M2 macrophage polarization, and restoring the balance of M1 / M2 macrophage polarization is also a potential strategy for the treatment of UC. Targeted therapy of macrophage polarization can reconstruct the homeostasis of the intestinal immune microenvironment and restore tissue homeostasis after inflammation. In addition, commensal flora also plays a vital role in maintaining intestinal homeostasis. Short-chain fatty acids (SCFAs), such as acetate, propionate, butyrate, and isobutyrate, are the main end products of intestinal microbial fermentation. Studies have shown that SCFAs are closely related to repairing the intestinal epithelial barrier, reducing inflammation, and promoting the development of immune cells. Regulating intestinal flora also plays an important role in the treatment of UC. In addition, members of the CXC chemokine ligand family (CXCL1, CXCL3, CXCL10) can enter the blood and cause a permanent inflammatory cycle, playing a key role in the development of UC. Among them, CXCL1 is considered to be associated with neutrophil infiltration. The immune system also plays an important role in the development of UC. The disruption of normal intestinal immune regulation or abnormal immune response is an important aspect of the pathogenesis of UC. Innate inflammatory neutrophils and monocytes produce an inflammatory environment (nutrition, metabolism, and cytokines) during the development of UC, thereby promoting pathological adaptive immune responses.

[0004] Based on the above-mentioned UC pathogenesis and clinical symptoms, the current treatment drugs mainly include aminosalicylic acids (such as mesalazine, sulfasalazine), glucocorticoids, immunosuppressants and biological agents (such as infliximab). Although these drugs can improve the patient's lifestyle, there are many problems. As the first choice of drugs for mild to moderate UC, aminosalicylic acid preparations are prone to cause gastrointestinal reactions in UC patients, and produce adverse reactions such as granulocytopenia and nephrotoxicity. For patients with severe UC, long-term use of glucocorticoids increases the risk of osteoporosis, Cushing's syndrome and peptic ulcers. The widely used immunosuppressants in clinical practice are cytotoxic, and long-term use can easily cause liver and kidney damage and bone marrow suppression. Biological agents such as TNF-α, JAK inhibitors, IL-12 / IL-23 antagonists, and integrin antagonists can inhibit over-activated intestinal mucosal immune responses, but there are still some shortcomings, such as drug intolerance, large individual differences in bioavailability, and high prices. Therefore, driven by this demand, it is urgent to find anti-UC drugs with definite efficacy, small toxicity and side effects, and novel mechanisms of action.

[0005] Kelch-like ECH-associated protein 1 (Keap1) is a cysteine-rich homodimer containing 624 amino acids and composed of 5 domains, of which the Kelch domain is responsible for binding to the N-terminal Neh2 domain of Nrf2. By regulating the redox of its cysteine, the dimerization state of the protein, and interfering with the binding of the substrate protein Nrf2, it leads to the expression of antioxidant and anti-inflammatory genes in the nucleus. The Keap1 / Nrf2 signaling pathway is one of the most important defense mechanisms. It can resist intracellular oxidative stress damage and is closely related to the occurrence of inflammatory diseases. Many studies have shown that Keap1 is a potential target for the treatment of UC. By regulating Keap1 and promoting the nuclear entry of Nrf2, cellular inflammatory factors can be reduced and UC can be effectively improved.

[0006] Keap1 inhibitors can be divided into macromolecular inhibitors and small molecule inhibitors. Macromolecular inhibitors are mainly highly active peptides and analogs designed based on a sequence of Nrf2. Due to their large molecular weight and poor ability to penetrate the cell membrane, their activity is greatly reduced; small molecule inhibitors are divided into covalent and non-covalent inhibitors. Non-covalent inhibitors include phenylpropidine, naphthylamide, benzothiazolyl heterocycles, etc., which have insufficient biological activity, weak binding ability and off-target phenomena. The other is a covalent inhibitor, which covalently modifies the cysteine ​​Cys151, Cys273 and Cys288 in the BTB and IVR domains of Keap1, thereby blocking the interaction between Keap1 and Cul3 and interfering with the ubiquitination of Nrf2. This type of inhibitor has too high affinity, making Nrf2 abnormally active, leading to an imbalance in ROS levels and the risk of carcinogenesis. Therefore, the development of new Keap1 inhibitors that can both specifically activate Nrf2 and maintain the balance of Keap1 / Nrf2 is a bottleneck problem that urgently needs to be broken through.

[0007] The purpose of the present invention is to find and develop compounds with anti-ulcerative colitis effects, which mainly target Kelch-like ECH-associated protein 1 (Keap1), regulate its downstream Nrf2 and DDX5 proteins, inhibit the synthesis of pro-inflammatory factors, and promote the production of anti-inflammatory factors, thereby treating ulcerative colitis. Compared with aminosalicylic acid drugs such as mesalazine commonly used in the clinical treatment of ulcerative colitis, they have comparable or even better efficacy. Summary of the invention

[0008] Based on the above purpose, the present invention first provides a glycoside compound targeting Keap1, wherein the compound has the structural formula (I), (I),

[0009] in: The aromatic ring (Ar) is a benzene ring, a naphthalene ring, an anthracene ring or an aromatic heterocycle containing N, O and S, such as pyridine, thiazole, pyrrole and furan. The aromatic ring has no substituent or has a substituent R1, and the substituent R1 can be monosubstituted or polysubstituted. In a preferred embodiment, the substituent can include but is not limited to any combination of the following functional groups: halogens such as fluorine, chlorine and bromine, hydroxyl, cyano, nitro, amino, ester, amide, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, C 1-6 Haloalkyl, C 1-6 Alkylthio;

[0010] m is 0, 1 or 2; X is O or NH; Y is selected from linear or branched alkyl, alkenyl and alkynyl groups containing 1 to 8 carbon atoms, wherein the substituents on the chain can be independently selected from halogen, hydroxyl, amino, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, C 1-6 Alkylthio or any combination of these functional groups;

[0011] W is a glycosyl group.

[0012] In a preferred embodiment, the glycosyl group is a mono- or poly-substituted five- or six-membered monosaccharide or polysaccharide; More preferably, the monosaccharide includes but is not limited to the following monosaccharides or any combination of monosaccharides: glucose, mannose, rhamnose, fucose, ribose, galactose, arabinose and uronic acid, etc. In a specific embodiment of the present invention, the monosaccharide includes glucose, mannose and fucose.

[0013] In a preferred embodiment, the glycosyl substituent may be methyl, acetyl, or benzoyl.

[0014] As used herein, the term "halogen (halo)" refers to fluorine (fluoro), chlorine (chloro), bromine (bromo) or iodine (iodo).

[0015] As used herein, the term "aryl" refers to a 5-12 membered substituted or unsubstituted aromatic system, or may include a fused bicyclic aromatic system, including but not limited to phenyl and naphthyl.

[0016] The term "heteroaromatic ring" as used herein refers to a 5-12 membered substituted or unsubstituted heterocyclic aromatic system, or may include a fused bicyclic heterocyclic aromatic system, including but not limited to thienyl, furanyl, pyridinyl, quinolyl, pyrrolyl, thiazolyl, oxazolyl.

[0017] In a specific embodiment of the present invention, the glycoside compound targeting Keap1 is a compound having the following structural formula: (1) ( S )-3-hydroxy-2-methenyl-4-( β - D -Glucose oxy)butyl ( E )-3-(3,4-dihydroxyphenyl)acrylate (C 20 H 26 O 11 ), ;

[0018] (2) 3-Hydroxy-2-methenyl-4-( β - D -Glucose oxy)butyl (E )-3-(3,4-dihydroxyphenyl)acrylate (C 20 H 26 O 11 ), ; (3) ( S )-4-hydroxy-2-methenyl-3-( β - D -Glucose oxy)butyl ( E )-3-(3,4-dihydroxyphenyl)acrylate (C 20 H 26 O 11 ), ; (4) ( S )-3-hydroxy-4-( β - D -Glucose oxy)butyl ( E )-3-(3,4-dihydroxyphenyl)acrylate (C 19 H 26 O 11 ), ; (5) 2-Hydroxy-3-( β - D -Glucose oxy)propyl ( E )-3-(3,4-dihydroxyphenyl)acrylate (C 18 H 24 O 11 ), ; (6) ( E )-3-(3,4-dihydroxyphenyl)- N -(( S )-3-hydroxy-4-( β - D -glucoseoxy)butyl)acrylamide (C 19 H 27 NO 10 ), ; (7) ( S )-3-hydroxy-4-( β - D -Glucose oxy)butyl ( E )-3-(3,4-dimethoxyphenyl)acrylate (C 21 H 30 O 11 ), ; (8) ( S )-3-hydroxy-4-( β - D -Glucose oxy) butyl cinnamate (C 19 H 26 O9), ; (9) 2-Hydroxy-3-( β - D -Glucose oxy)propyl ( E )-3-(4-hydroxyphenyl)acrylate (C 18 H 24 O 10 ), ; (10) ( S )-3-hydroxy-4-( β - D -Glucose oxy)butyl ( E )-3-(p-methylphenyl)acrylate (C 20 H 28 O9), ; (11) ( S )-3-hydroxy-4-( β - D -Glucose oxy)butyl ( E )-3-(4-chlorophenyl) acrylate (C 19 H 25 ClO9), ; (12) ( S )-3-hydroxy-4-(2,3,4,6-tetramethoxy- β - D -Glucose oxy)butyl ( E )-3-(3,4-dimethoxyphenyl)acrylate (C 25 H 38 O 11 ), ; (13) ( S )-3-hydroxy-4-(2,3,4,6-tetrabenzoyl- β - D -Glucose oxy)butyl ( E )-3-(3,4-dihydroxyphenyl)acrylate (C47 H 42 O 15 ), ; (14) 3-tert-hydroxy-2-methenyl-4-(2,3,4,6-tetraacetoxy- β - D -Glucose oxy)butyl ( E )-3-(3,4-dihydroxyphenyl)acrylate (C 28 H 34 O 15 ), ; (15) N -3-( β - D -Glucose oxy)propyl ( E )-3-(3,4-dihydroxyphenyl)acrylamide (C 18 H 25 NO9), ; (16) N -4-( β - D -Glucose oxy)butyl ( E )-3-(3,4-dihydroxyphenyl)acrylamide (C 19 H 27 NO9), ; (17) ( R )-2-methyl-4-( β - D -Glucose oxy)propyl ( E )-3-(3,4-dihydroxyphenyl)acrylate (C 19 H 26 O 10 ), ; (18) ( E )-2-methyl-4-( β - D -glucoseoxy)but-2-en-1-yl( E )-3-(3,4-dihydroxyphenyl)acrylate (C 20 H 26 O 10 ), ; (19) ( S)-3-hydroxy-4-( β - D -Glucose oxy) butyl 3-(3,4-dihydroxyphenyl) propionate (C 19 H 28 O 11 ), ; (20) ( S )-3-hydroxy-4-( β - D -Glucose oxy) butyl benzoate (C 17 H 24 O9),

[0019] ; (twenty one) ( S )-3-hydroxy-4-( β - D -fucosyl)butyl( E )-3-(3,4-dihydroxyphenyl)acrylate (C 19 H 26 O 10 ), ;or (twenty two) ( S )-3-hydroxy-4-(2,3,4,6-tetraacetoxy- β - D -mannoseoxy)butyl( E )-3-(3,4-dihydroxyphenyl)acrylate (C 27 H 34 O 15 ), .

[0020] The present invention also relates to various isomers of the compound. In a preferred embodiment, the glycoside compound targeting Keap1 is a racemate, optical isomer, optical isomer, or tautomer compound of the above-mentioned compound. Some compounds in the present invention may exist in the form of optical isomers or tautomers, and the present invention includes all forms thereof, especially pure isomeric forms. Different isomeric forms can be separated or split from other forms of isomers by various conventional means, or a certain isomer can be obtained by various conventional synthesis methods or stereospecific or asymmetric synthesis methods. In the application of the compounds of general formula (I) for pharmaceutical purposes, it can be understood that they are preferably provided in a pure form, for example, 60% purity, more preferably 75%, better 85%, and preferably at least 98% purity. The preparation method of the impure compound can be used for a purer form in a pharmaceutical composition.

[0021] In a preferred embodiment, the glycoside compound targeting Keap1 is a pharmaceutically acceptable salt, pharmaceutically acceptable ester, amide derivative, or pharmaceutically acceptable solvate thereof of the above-mentioned compound. Some compounds of the present invention may be crystallized or recrystallized with water or various organic solvents, in which case various solvates may be formed. The present invention includes solvates of all chemical doses, including hydrates, and also includes compounds containing variable amounts of water formed when prepared by low-pressure sublimation drying, such as monohydrates, dihydrates, etc.

[0022] Secondly, the present invention provides a synthetic method for preparing the above-mentioned glycoside compounds targeting Keap1. The compounds of general formula (I) can be prepared by artificial synthesis from known or commercially available compounds as raw materials. If the raw materials are not commercially available, their preparation methods are provided here, or they can be prepared by literature reports or similar methods.

[0023] Specifically, the present invention provides a method for preparing the above-mentioned glycoside compound targeting Keap1 or a solvate thereof, which comprises: Method 1: (1) First, a substituted aromatic acid and a polyhydroxyalkyl chain undergo a condensation reaction to prepare a substituted aromatic acid ester or amide. ,

[0024] Wherein, R1, m, X and Y are defined as in the compound of general formula (I). R2 is a hydroxyl protecting group, including but not limited to the following groups: tert-butyldimethylsilyl, tert-butyldiphenylsilyl, trimethylsilyl, triethylsilyl, benzyl, methyl, tert-butyl, acetyl, benzoyl, p-methoxybenzyl, trityl, methoxymethyl, methoxyethoxymethyl and tetrahydropyran, etc.

[0025] (2) The substituted aromatic acid ester or amide intermediate is subjected to appropriate conditions to remove the hydroxyl protecting group R2

[0026] wherein R1, m, X and Y are as defined in the compound of formula (I).

[0027] (3) The substituted aromatic acid ester or amide after removal of the hydroxy protecting group undergoes glycosidation reaction with a glycosyl donor to obtain a compound of formula (I).

[0028]

[0029] Wherein, R1, m, X, Y and W are defined as in the compound of general formula (I). R3 includes but is not limited to the following groups: alkylthio, arylthio, trichloroacetonitrile and acetoxy.

[0030] Method 2: (1) First, a polyhydroxyalkyl chain is reacted with a glycoside donor to undergo glycosylation to prepare an alkyl glycoside.

[0031] Wherein, X, Y and W are defined as in the compound of general formula (I). R3 includes, but is not limited to, the following groups: alkylthio, arylthio, trichloroacetonitrile and acetoxy. R4 is a protecting group for hydroxyl or amino, including, but not limited to, the following groups: tert-butyldimethylsilyl, tert-butyldiphenylsilyl, trimethylsilyl, triethylsilyl, benzyl, methyl, tert-butyl, acetyl, benzoyl, p-methoxybenzyl, trityl, methoxymethyl, methoxyethoxymethyl, tetrahydropyran and tert-butoxyacyl.

[0032] (2) The alkyl glycoside intermediate is subjected to appropriate conditions to remove the protective group R4 of the hydroxyl or amino group.

[0033] wherein X, Y and W are as defined in the compound of formula (I).

[0034] (3) The alkyl glycoside after removing the protecting group on X undergoes a condensation reaction with a substituted aryl acid ester to obtain a compound of the general formula (I).

[0035]

[0036] wherein R1, m, X, Y and W are as defined in the compound of formula (I).

[0037] In the process of synthesizing the above-mentioned glycoside compounds targeting Keap1, there are groups that are volatile or have adverse effects on the reaction process, such as phenolic hydroxyl, alcoholic hydroxyl, and hydroxyl and amino groups on sugars, which can be protected first and then deprotected in an appropriate step. The protection and deprotection of functional groups have been discussed in detail in relevant literature such as Protective groups in organic chemistry TW Greene and PGM Wuts, (Wiley-Interscience, New York, 2nd edition, 1991). It can also exist in the form of its potential functional group first and be converted into the desired functional group in an appropriate step, such as the amino group can first exist in the form of azide.

[0038] Finally, the present invention provides the use of the above-mentioned glycoside compounds targeting Keap1 in the preparation of therapeutic drugs for diseases caused by abnormal activity of Kelch-like ECH-associated protein 1. The Kelch-like ECH-associated protein 1 described in the present invention, i.e. Keap1, has a Kelch domain responsible for binding to the N-terminal Neh2 domain of Nrf2. When the activity of Keap1 increases, it is sufficient to prevent Nrf2 from entering the nucleus and initiating the transcriptional expression of antioxidant and anti-inflammatory genes in the nucleus. The technical effect of the above-mentioned compounds provided by the present invention in inhibiting the release of inflammatory factors in mouse models is difficult to be maintained in mouse models after the Keap1 gene is knocked out, proving that the compounds act through the Keap1-related signaling pathway, that is, through the combination of the compounds with Keap1, highly effective anti-inflammatory activity is produced. Therefore, in the application of the present invention, the above-mentioned glycoside compounds are used as drugs targeting Keap1.

[0039] In a preferred embodiment of the present invention, the disease caused by abnormal activity of the above-mentioned Kelch-like ECH-associated protein 1 is mainly ulcerative colitis. Based on the fact that the Keap1 / Nrf2 signaling pathway also plays an important role in treating intestinal mucosal damage in mice with ulcerative colitis, maintaining the integrity of intestinal epithelial cells, and repairing epithelial cell damage to resist colitis, the purpose of the present invention is to find and develop small molecule compounds with anti-ulcerative colitis effects, aiming to treat ulcerative colitis by targeting Kelch-like ECH-associated protein 1 (Keap1. Therefore, the above-mentioned compounds provided by the present invention can specifically target Keap1, thereby inhibiting the synthesis of pro-inflammatory factors, while promoting the production of anti-inflammatory factors, reducing the degree of inflammatory response of intestinal epithelial cells, repairing inflammatory damage, and maintaining the integrity of intestinal epithelial cells, thereby achieving the purpose of treating ulcerative colitis.

[0040] In the above-mentioned application of the present invention, the above-mentioned glycoside compound targeting Keap1 or its pharmaceutically acceptable solvate can be used alone, or used in the form of a pharmaceutical composition together with a pharmaceutically acceptable carrier or excipient. When it is used in the form of a pharmaceutical composition, an effective dose of the compound or its pharmaceutically acceptable solvate and one or more pharmaceutically acceptable carriers or diluents are usually combined to form a suitable administration form or dosage form, and this procedure includes mixing, granulating, compressing or dissolving the composition in a suitable manner. Therefore, the present invention provides a pharmaceutical composition, which contains all possible isomers or pharmaceutically acceptable solvates of glycoside compounds targeting Keap1 and at least one pharmaceutically acceptable carrier.

[0041] The pharmaceutical composition of the present invention can be administered in any of the following ways: oral, spray inhalation, rectal, topical, injection such as subcutaneous, intravenous, intramuscular, intraperitoneal, or via an explanted reservoir, wherein oral, intraperitoneal or intravenous administration is preferred.

[0042] The compound of the present invention or its pharmaceutically acceptable solvate can be administered in a unit dosage form. The dosage form can be a liquid dosage form or a solid dosage form. The liquid dosage form can be a true solution, a colloid, a microparticle dosage form, an emulsion dosage form, or a suspension dosage form. Other dosage forms include tablets, capsules, dripping pills, aerosols, pills, powder injections, solutions, emulsions, granules, suppositories, inclusion compounds, patches, and liniments.

[0043] The pharmaceutical composition of the present invention may also contain commonly used carriers, including but not limited to: ion exchangers, aluminum oxide, aluminum stearate, buffer substances such as phosphates, glycerol, sorbic acid, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes. The content of the carrier in the pharmaceutical composition may be 1%-98% (by weight).

[0044] Tablets and capsules for oral administration may contain excipients such as binders including syrup, gum arabic, gum tragacanth, etc., fillers such as lactose, sucrose, corn starch, aminoacetic acid, etc., lubricants such as magnesium stearate, talc, silica, etc., disintegrants such as potato starch, etc., or acceptable wetting agents such as sodium lauryl sulfate, etc. Tablets may be coated by methods known in the pharmaceutical industry.

[0045] Oral liquid can be made into water and oil suspension, solution, emulsion or syrup, or can be made into dry product, and water or other suitable medium is added before use. Such liquid preparation can contain conventional additives, such as suspending agent, sorbitol, methyl cellulose, etc., emulsifier such as sorbitan monohydrate and gum arabic, etc. Flavoring agent or coloring agent can be added if necessary.

[0046] For extragastric administration, liquid dosage forms are usually made of the compound and a sterile carrier. The preferred carrier is water. Depending on the selected carrier and drug concentration, the compound can be dissolved in the carrier or made into a suspension. When making a solution for injection, the compound is first dissolved in water, filtered and sterilized, and then filled into a sealed bottle or ampoule.

[0047] Depending on the administration method, the composition may contain 1% by weight or more appropriate active ingredients. However, when the composition contains unit doses, each unit preferably contains 10-500 mg of active ingredients. Depending on the administration route and frequency of administration, the appropriate therapeutic dose for adults is 60-300 mg per day.

[0048] It should be recognized that the optimal dosage and interval of the compound of formula (I) is determined by the properties of the compound and external conditions such as the form, route and site of administration and the specific mammal to be treated, and this optimal dosage can be determined by conventional techniques. At the same time, it should also be recognized that the optimal course of treatment, that is, the daily dosage of the compound of formula (I) within a specified period of time can be determined by methods known in the art.

[0049] Compared with the currently commonly used anti-ulcerative colitis mesalazine in clinical practice, these compounds have equivalent or better anti-ulcerative colitis efficacy. For example, the compound described in Example 1 can effectively improve the weight loss of ulcerative colitis mice, reduce the disease activity index (DAI) of ulcerative colitis mice, and improve the symptoms of diarrhea, blood in the stool, weight loss, etc. of ulcerative colitis mice. At the same time, the compound described in Example 1 can improve the shortening of colorectal stenosis caused by ulcerative colitis. The results of HE staining showed that after low, medium and high doses of the compound described in Example 1 were given, intestinal mucosal ulcers were reduced, inflammatory cell infiltration was reduced, and the glandular arrangement tended to be normal, and it was dose-dependent. The high-dose group had the most significant effect, and the efficacy was better than the positive control drug mesalazine (first-line drug for ulcerative colitis). In addition, the compound described in Example 1 can effectively inhibit the expression of IL-6 and IL-1β mRNA, and reduce the levels of TNF-α, IL-6, and IL-1β in the peripheral blood and colon tissue of mice. In addition, in in vitro experiments, the compound described in Example 1 had no significant toxicity to NCM460 cells at 5-80 μM, and it could significantly inhibit the mRNA levels of proinflammatory factors IL-6 and IL-1β in NCM460 cells induced by TNF-α. BRIEF DESCRIPTION OF THE DRAWINGS

[0050] Figure 1 The compound described in Example 1 showed the efficacy of inhibiting the production of inflammatory factors in the RAW264.7 macrophage model induced by LPS; Figure 2 The results show the efficacy of the compound described in Example 1 in inhibiting the production of inflammatory factors in the inflammatory model of NCM460 cells induced by TNF-α and its effect on cell viability; Figure 3 The results show that some of the compounds in the examples have therapeutic effects on DSS-induced ulcerative colitis in mice. Figure 4 The curve showing the inhibition of DSS-induced weight loss in mice by the compound described in Example 1; Figure 5 The curve showing the inhibition of the increase of DAI in mice by the compound described in Example 1; Figure 6 It shows that the compound described in Example 1 inhibits the shortening and narrowing of the mouse colon; Figure 7 The expression of inflammatory factors IL-6 and IL-1β mRNA and the levels of TNF-α, IL-6, and IL-1β in the peripheral blood of mice during treatment with the compound described in Example 1 are shown; Figure 8 The results of colon HE staining during treatment with the compound described in Example 1 are shown; Fig. 9 It was shown that after knocking out Keap1, the therapeutic effect of the compound described in Example 1 was reduced.

[0051] Figure 1-Figure 9 wherein PBA is the compound described in Example 1, Mesalazine is mesalazine, P1 is the compound described in Example 5, P2 is the compound described in Example 9, P3 is the compound described in Example 4, and P4 is the compound described in Example 2. DETAILED DESCRIPTION

[0052] The present invention will be further described below in conjunction with specific embodiments, and the advantages and features of the present invention will become clearer as the description proceeds. However, these embodiments are merely exemplary and do not constitute any limitation on the scope of protection defined by the claims of the present invention.

[0053] Example 1: S )-3-hydroxy-2-methenyl-4-( β - D -Glucose oxy)butyl ( E Preparation of 3-(3,4-dihydroxyphenyl)acrylate

[0054] Step 1: Intermediate ( S Preparation of 3-methenyl-1,2,4-butanetriol Intermediate ( S Preparation method of )-3-methenyl-1,2,4-butanetriol Reference S Synthesis 2016, 48, 13, 2130-2136. In brief, 2,2-dihydroxyacetic acid and methyl 2,2-dimethoxyacetate are used as raw materials, and under the catalysis of p-toluenesulfonic acid, phosphorus pentoxide is used for dehydration to obtain methyl glyoxylate. Then, methyl glyoxylate and methyl acrylate are condensed under the catalysis of DABCO to obtain dimethyl 2-hydroxy-3-methylenylsuccinate. Under the catalysis of Amano lipase PS, S -configuration of dimethyl 2-hydroxy-3-methenylsuccinate and vinyl acetate selectively undergoes acetylation to obtain ( S )-2-acetoxy-3-methylenylsuccinate. Then, under the action of hydrochloric acid, ( S )-2-acetoxy-3-methylenylsuccinic acid dimethyl ester is deacetylated to obtain ( S )-2-hydroxy-3-methenyl succinic acid dimethyl ester. S After the hydroxyl group of )-2-hydroxy-3-methylenylsuccinate was protected with TBS, dimethyl succinate was reduced with DIBAl-H to obtain (S)-2-((tert-butyldimethylsilyl)oxy)-3-methylenyl 1,4-butanediol. Finally, the TBS protecting group was removed to obtain the target intermediate ( S)-3-methenyl-1,2,4-butanetriol.

[0055] Step 2: Intermediate ( S Preparation of 2-(2,2-dimethyl-1,3-dioxolan-4-yl)propyl-2-en-1-ol Will( S )-3-Methenyl-1,2,4-butanetriol (5.0 g, 42.4 mmol) and p-toluenesulfonic acid monohydrate (0.40 g, 0.4 g) were dissolved in 50 mL of acetone, stirred at room temperature for 3 h, and then sodium bicarbonate aqueous solution was added to adjust the pH to 7-8. The mixture was concentrated under reduced pressure to recover the acetone, and then diluted with ethyl acetate and washed with water. The ethyl acetate layer was concentrated under reduced pressure to obtain the target intermediate. 1 H NMR (400 MHz, CDCl3) δ 5.21 – 5.02 (m, 2H), 4.62 (t, J = 7.1 Hz, 1H), 4.16 (d, J =13.3 Hz, 1H), 4.11 – 4.05 (m, 2H), 3.66 (t, J = 8.0 Hz, 1H), 1.40 (s, 3H), 1.33(s, 3H). Step 3: E Preparation of 3-(3,4-di(tert-butyldimethylsilyl)oxy)phenyl)acrylic acid Dissolve caffeic acid (20.0 g, 0.11 mol) and imidazole (37.8 g, 0.55 mol) in 200 mL of dichloromethane. Slowly add a dichloromethane solution of tert-butyldimethylsilyl chloride (83.0 g, 0.55 mol) to the reaction flask under an ice bath. Stir and react at room temperature for 6 h. Subsequently, add potassium carbonate solution to the reaction flask, stir and react for 2 h, and separate the dichloromethane layer. Extract the water layer twice with dichloromethane, combine the dichloromethane layers, and concentrate. The target intermediate is obtained after crystallization from ethanol-water. 1 H NMR (400 MHz, Chloroform- d ) δ 7.69 (d, J = 16.0 Hz, 1H), 7.08 – 7.00(m, 2H), 6.87 – 6.79 (m, 1H), 6.25 (d, J = 16.0 Hz, 1H), 1.00 (s, 9H), 0.99 (s, 9H), 0.23 (s, 6H), 0.22 (s, 6H).

[0056] Step 4: S )-2-(2,2-dimethyl-1,3-dioxolan-4-yl)allyl( E )-3-(3,4-di((tert-butyldimethylsilyl)oxy)phenyl)acrylate Will( E )-3-(3,4-di(tert-butyldimethylsilyl)oxy)phenyl)acrylic acid (5.0 g, 12.2 mmol), (S)-3-methenyl-1,2,4-butanetriol (1.6 g, 10.2 mmol), 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (2.35 g, 12.2 mmol) and 4-dimethylaminopyridine (0.2 g, 2.0 mmol) were dissolved in 50 mL of dichloromethane and stirred at room temperature for 8 h. After the reaction was completed, the mixture was diluted with dichloromethane and washed with water. The dichloromethane layer was concentrated under reduced pressure and purified by column chromatography to obtain the target compound. 1 H NMR (400 MHz, CDCl3) δ 7.59 (d, J = 15.9 Hz, 1H), 7.02 (d, J =7.0 Hz, 2H), 6.88 – 6.75 (m, 1H), 6.24 (d, J = 15.9 Hz, 1H), 5.39 (s, 1H), 5.28(s, 1H), 4.86 – 4.67 (m, 2H), 4.65 (dd, J = 7.7, 6.4 Hz, 1H), 4.19 (dd, J = 8.2,6.5 Hz, 1H), 3.77 (t, J = 7.9 Hz, 1H), 1.46 (s, 3H), 1.41 (s, 3H), 1.00 (s, 9H), 0.99 (s, 9H), 0.22 (s, 6H), 0.21 (s, 6H).

[0057] Step 5: S )-3,4-dihydroxy-2-methenylbutyl (E)-3-(3,4-di((tert-butyldimethylsilyl)oxy)phenyl) acrylate The above ( S )-2-(2,2-dimethyl-1,3-dioxolan-4-yl)allyl( E)-3-(3,4-di((tert-butyldimethylsilyl)oxy)phenyl)acrylate (4.0 g, 7.8 mmol) was dissolved in a mixed solution of acetic acid and water (acetic acid: water = 4:1, 40 mL) and reacted at 60°C for 2 h. The reaction solution was diluted with dichloromethane, washed with saturated sodium bicarbonate and then with water, and the dichloromethane layer was concentrated under reduced pressure to obtain a crude product. 1 H NMR (400 MHz, CDCl3) δ 7.61 (d, J = 16.0 Hz, 1H), 7.03-7.00 (m, 2H), 6.82 (d, J = 6.8 Hz, 1H), 6.24 (d, J = 16.0 Hz, 1H), 5.40 (s, 1H), 5.28 (s, 1H), 4.87 – 4.68 (m, 2H), 4.65 (dd, J = 7.7, 6.4 Hz, 1H), 4.19 (dd, J =8.2, 6.5 Hz, 1H), 3.77 (t, J = 7.9 Hz, 1H), 0.99 (s, 9H), 0.98 (s, 9H), 0.22 (s, 6H), 0.21 (s, 6H). Step 6: S )-4-((tert-butyldimethylsilyl)oxy)-3-hydroxy-2-methenylbutyl( E )-3-(3,4-di(tert-butyldimethylsilyl)oxy)phenyl)acrylate The above ( S )-4-((tert-butyldimethylsilyl)oxy)-3-hydroxy-2-methenylbutyl( E )-3-(3,4-di(tert-butyldimethylsilyl)oxy)phenyl)acrylate (3.0 g, 5.9 mmol) and imidazole (0.5 g, 7.6 mmol) were dissolved in dichloromethane. Tert-butyldimethylsilyl chloride (1.2 g, 7.8 mmol) was slowly added to the reaction bottle under ice bath. The reaction was stirred at room temperature for 1 h. The reaction solution was diluted with dichloromethane, washed with water, and the dichloromethane layer was concentrated under reduced pressure to obtain a crude product. 1 H NMR (400 MHz,CDCl3) δ 7.60 (d, J = 16.0 Hz, 1H), 7.02-6.99 (m, 2H), 6.82 (d, J = 6.8 Hz, 1H),6.23 (d,J = 16.0 Hz, 1H), 5.39 (s, 1H), 5.28 (s, 1H), 4.87 (s, 2H), 4.65 (dd, J = 7.7, 6.4 Hz, 1H), 4.19 (dd, J = 8.2, 6.5 Hz, 1H), 3.77 (t, J = 7.9 Hz, 1H), 0.99 (s, 9H), 0.98 (s, 9H), 0.92 (s, 9H), 0.22 (s, 6H), 0.21 (s, 6H), 0.10 (s, 6H). Step 7: ( S )-4-((tert-butyldimethylsilyl)oxy)-3-((tert-butyldimethylsilyl)oxy)-2-methenylbutyl( E )-3-(3,4-di((tert-butyldimethylsilyl)oxy)phenyl)acrylate The above ( S )-4-((tert-butyldimethylsilyl)oxy)-3-((tert-butyldimethylsilyl)oxy)-2-methenylbutyl (E)-3-(3,4-di((tert-butyldimethylsilyl)oxy)phenyl)acrylate (5.0 g, 8.0 mmol) and imidazole (1.1 g, 16.1 mmol) were dissolved in N,N -dimethylamide, tert-butyldiphenylsilyl chloride (2.8 g, 10.4 mmol) was slowly added to the reaction bottle under ice bath, and reacted at 80°C for 10 h. The reaction solution was diluted with ethyl acetate, washed with water, and the ethyl acetate layer was concentrated under reduced pressure to obtain a crude product.

[0058] Step 8: ( S )-3-((tert-butyldiphenyl)oxy)-4-hydroxy-2-methenylbutyl( E )-3-(3,4-di(tert-butyldimethylsilyl)oxy)phenyl)acrylate The above ( S )-3-((tert-butyldiphenyl)oxy)-4-hydroxy-2-methenylbutyl( E )-3-(3,4-di(tert-butyldimethylsilyl)oxy)phenyl)acrylate (5.0 g, 6.7 mmol) was dissolved in tetrahydrofuran (50 mL), and 16% trifluoroacetic acid-water solution (27 mL, 53.6 mmol) was slowly added dropwise at 10°C. After the addition, the mixture was reacted at 10°C for 8 h. The reaction solution was diluted with ethyl acetate, washed with saturated sodium bicarbonate and water, and the ethyl acetate layer was concentrated under reduced pressure and purified by column chromatography to obtain the target compound.

[0059] Step 9: 2R,3R,4S,5R,6S )-2-((Benzoyloxy)methyl)-6-(2,2,2-trichloro-1-iminoethoxy)tetrahydro-2 H -Pyran-3,4,5-benzoate Intermediate ( 2R,3R,4S,5R,6S )-2-((Benzoyloxy)methyl)-6-(2,2,2-trichloro-1-iminoethoxy)tetrahydro-2 H -Preparation references of pyran-3,4,5-benzoate J. Med. Chem. 2024, 67, 9976−9990. Briefly, glucose and benzoyl chloride were used as raw materials to obtain 1,2,3,4,6-pentabenzoyloxyglucose under the action of triethylamine. Then, under the action of hydrazine acetate, 1,2,3,4,6-pentabenzoyloxyglucose selectively removed the 1-benzoyl group to obtain 2,3,4,6-tetrabenzoyloxyglucose. Finally, 2,3,4,6-tetrabenzoyloxyglucose and trichloroacetonitrile were converted into the target intermediate under the catalysis of 1,8-diazabicyclo[5.4.0]undec-7-ene and used directly in the next step.

[0060] Step 10: ( S )-3-tert-butyldiphenylsilyloxy-2-methyl-4-(2,3,4,6-tetrabenzoyl- β - D -Glucose oxy)butyl ( E )-3-(3,4-tert-Butyldimethylsilyloxyphenyl)acrylate The result of the previous step ( 2R,3R,4S,5R,6S )-2-((Benzoyloxy)methyl)-6-(2,2,2-trichloro-1-iminoethoxy)tetrahydro-2 H -pyran-3,4,5-benzoate (2.0 g, 2.7 mmol), (S)-3-((tert-butyldiphenyl)oxy)-4-hydroxy-2-methenylbutyl ( E )-3-(3,4-di(tert-butyldimethylsilyl)oxy)phenyl)acrylate (1.7 g, 2.3 mmol) and baked molecular sieves (2.5 g) were placed in a round-bottom flask, and anhydrous dichloromethane (20 mL) was added after replacing the gas three times. After stirring for 3 h under a nitrogen atmosphere, trimethylsilyl trifluoromethanesulfonate (0.1 mL, 0.46 mmol) was added in an ice bath and stirred at room temperature for 2 h. The reaction solution was quenched with saturated sodium bicarbonate aqueous solution, filtered, and the filtrate was diluted with dichloromethane and washed with water. The organic layer was concentrated under reduced pressure to obtain the target intermediate. 1H NMR (400 MHz, CDCl3) δ 8.02 – 8.00(m, 2H), 7.91 – 7.81 (m, 6H), 7.61 – 7.25 (m, 25H),7.16 (dd, J = 8.0, 2.0 Hz,1H), 6.96 (dt, J = 8.0, 2.0 Hz, 1H), 6.90 (dd, J = 8.2, 1.4 Hz, 1H), 6.23 (d, J =16.0 Hz, 1H), 5.96 (td, J = 9.7, 2.7 Hz, 1H), 5.74 (td, J = 9.8, 7.5 Hz, 1H),5.59 (ddd, J = 9.8, 7.9, 5.5 Hz, 1H), 5.37 – 5.25 (m, 1H), 5.20 (d, J = 5.7 Hz,1H), 4.97 (d, J = 7.9 Hz, 1H), 4.78 – 4.58 (m, 3H), 4.56 – 4.36 (m, 2H), 4.24 –4.19 (m, 1H), 3.97 – 3.85 (m, 1H), 3.72 – 3.67 (m, 1H), 1.0 (s, 9H), 0.99 (s,9H), 0.95 (s, 9H), 0.21 (s, 6H), 0.16 (s, 6H).

[0061] Step 11: ( S )-3-hydroxy-2-methenyl-4-(2,3,4,6-tetrabenzoyl- β - D -Glucose oxy)butyl ( E )-3-(3,4-dihydroxyphenyl)acrylate The result of the previous step ( S )-3-tert-butyldiphenylsilyloxy-2-methyl-4-(2,3,4,6-tetrabenzoyl- β - D -Glucose oxy)butyl ( E)-3-(3,4-tert-butyldimethylsilyloxyphenyl)acrylate (2.0 g, 1.5 mmol) was dissolved in tetrahydrofuran (20 mL), and tetrabutylammonium fluoride solution (7.5 mL, 7.5 mmol) was added under ice bath. After reacting for 12 h, the mixture was quenched with saturated ammonium chloride solution, diluted with ethyl acetate, and washed with water. The ethyl acetate layer was concentrated under reduced pressure and purified by column chromatography to obtain the target compound. 1 H NMR (400 MHz, CDCl3) δ 8.16 – 7.83 (m, 6H), 7.66 – 7.25 (m,15H), 7.17 (dd, J = 9.0, 2.0 Hz, 1H), 6.99 (dt, J = 8.3, 1.7 Hz, 1H), 6.91 (dd, J =8.2, 1.4 Hz, 1H), 6.23 (dd, J = 15.9, 4.0 Hz, 1H), 5.96 (td, J = 9.7, 2.7 Hz,1H), 5.74 (td, J = 9.8, 7.5 Hz, 1H), 5.59 (ddd, J = 9.8, 7.9, 5.5 Hz, 1H), 5.37 –5.25 (m, 1H), 5.20 (d, J = 5.7 Hz, 1H), 4.97 (d, J = 7.9 Hz, 1H), 4.78 – 4.58 (m,3H), 4.56 – 4.36 (m, 2H), 4.24 – 4.19 (m, 1H), 3.97 – 3.85 (m, 1H), 3.72 –3.67 (m, 1H). Step 12: ( S )-3-hydroxy-2-methenyl-4-( β - D -Glucose oxy)butyl ( E Preparation of 3-(3,4-hydroxyphenyl)acrylate The result of the previous step ( S )-3-hydroxy-2-methenyl-4-(2,3,4,6-tetrabenzoyl-β-D-glucoseoxy)butyl( E)-3-(3,4-dihydroxyphenyl)acrylate (1.0 g, 1.1 mmol) was dissolved in methanol (10 mL), and lithium hydroxide methanol solution (88 mL, 0.05 M) was slowly added dropwise at -5°C. The reaction was continued for 8 h, and then acidic resin (2 g) was added to quench the reaction. The reaction was diluted with water, extracted with ethyl acetate, washed with water, and the aqueous layer was concentrated and freeze-dried to obtain the target compound. A yellow foamy solid, 1 H NMR (400 MHz, CD3OD) δ 7.58 (d, J = 16.0 Hz, 1H), 7.08 (d, J = 2.0 Hz, 1H), 6.97 (dd, J = 8.0,2.0 Hz, 1H), 6.82 (d, J = 8.0 Hz, 1H), 6.31 (d, J = 16.0 Hz, 1H), 5.37 (s, 1H), 5.28 (s, 1H), 4.77 – 4.74 (m, 2H), 4.46 – 4.40 (m, 1H), 4.36 (d, J = 7.6 Hz,1H), 4.03 – 3.87 (m, 2H), 3.79 (dd, J = 10.8, 3.4 Hz, 1H), 3.70 (dd, J = 12.0,4.6 Hz, 1H), 3.45 – 3.26 (m, 4H). 13 C NMR (100 MHz, CD3OD) δ 168.98, 149.62,147.37, 146.75, 145.21, 127.70, 123.21, 116.67, 115.37, 115.10, 114.91,104.24, 77.90, 77.85, 75.03, 74.02, 72.36, 71.52, 65.56, 62.67.

[0062] Example 2: 3-hydroxy-2-methenyl-4-( β - D -Glucose oxy)butyl ( E )-3-(3,4-dihydroxyphenyl)acrylate

[0063] Using 2,2-dihydroxyacetic acid and methyl 2,2-dimethoxyacetate as raw materials, under the catalysis of p-toluenesulfonic acid, dehydration with phosphorus pentoxide gave methyl glyoxylate. Then, methyl glyoxylate and methyl acrylate were condensed under the catalysis of DABCO to give 2-hydroxy-3-methylenylsuccinic acid dimethyl ester. After the hydroxyl group of 2-hydroxy-3-methylenylsuccinic acid dimethyl ester was protected with TBS, dimethyl succinate was reduced with DIBAl-H to give 2-((tert-butyldimethylsilyl)oxy)-3-methylenyl 1,4-butanediol. Finally, the TBS protecting group was removed to give the intermediate 3-methylenyl-1,2,4-butanetriol. Then, using 3-methylenyl-1,2,4-butanetriol as raw material, the title compound was prepared in the same manner as described in Example 1. Yellow foamy solid, 1 H NMR (400 MHz, CD3OD) δ 7.57 (d, J = 16.0 Hz, 1H), 7.05 (d, J = 2.0 Hz, 1H), 6.96 (dd, J = 8.0,2.0 Hz, 1H), 6.78 (d, J = 8.0 Hz, 1H), 6.29 (d, J = 16.0 Hz, 1H), 5.35 (s, 1H), 5.27 (s, 1H), 4.82 – 4.67 (m, 2H), 4.43 – 4.41 (m, 1H), 4.32 (dd, J = 7.7, 3.1Hz, 1H), 4.68 – 3.54 (m, 4H), 3.39 – 3.20 (m, 4H).

[0064] Example 3: S )-4-hydroxy-2-methenyl-3-( β - D -Glucose oxy)butyl ( E )-3-(3,4-dihydroxyphenyl)acrylate The intermediate obtained in step 6 of Example 1 ( S )-4-((tert-butyldimethylsilyl)oxy)-3-hydroxy-2-methenylbutyl( E )-3-(3,4-di(tert-butyldimethylsilyl)oxy)phenyl)acrylate is used as a raw material, and the title compound is prepared through glycosylation reaction, TBS removal and benzoyl removal in step 10 to step 12. Yellow solid, 1 H NMR (400 MHz, CD3OD) δ 7.61 (d, J= 16.0Hz, 1H), 7.08 (d, J = 2.0 Hz, 1H), 6.98 (d, J = 8.1 Hz, 1H), 6.81 (d, J = 8.2 Hz,1H), 6.32 (d, J = 16.0 Hz, 1H), 5.61 (s, 1H), 5.28 (s, 1H), 4.43 – 4.41 (m,1H), 4.37 (d, J = 7.8 Hz, 1H), 4.30 – 4.10 (m, 2H), 4.01 – 3.58 (m, 4H), 3.41(d, J = 8.6 Hz, 4H).

[0065] Example 4: S )-3-hydroxy-4-( β - D -Glucose oxy)butyl ( E )-3-(3,4-dihydroxyphenyl)acrylate

[0066] by( S )-1,2,4-butanetriol as raw material and prepared by step 2 of Example 1 ( S Then, (S)-2-(2,2-dimethyl-1,3-dioxolan-4-yl)ethyl-1-ol and ( E )-3-(3,4-di(tert-butyldimethylsilyl)oxy)phenyl)acrylic acid was used as the raw material, and the title compound was prepared by steps 4-12 of Example 1. Yellow solid, 1 H NMR (400 MHz, CD3OD) δ 7.56 (d, J = 16.0Hz, 1H), 7.07 (d, J = 2.0 Hz, 1H), 6.96 (dd, J = 8.2, 2.1 Hz, 1H), 6.81 (d, J = 8.2Hz, 1H), 6.28 (d, J = 16.0 Hz, 1H), 4.43 – 4.18 (m, 3H), 4.05 – 3.93 (m, 2H), 3.88 (dd, J= 11.9, 1.5 Hz, 1H), 3.76 – 3.62 (m, 2H), 3.54 – 3.49 (m, 1H), 3.31 – 3.23 (m, 2H), 2.00 – 1.88 (m, 1H), 1.87 – 1.75 (m, 1H).

[0067] Example 5: 2-Hydroxy-3-( β - D -Glucose oxy)propyl ( E )-3-(3,4-dihydroxyphenyl)acrylate

[0068] Using glycerol as a raw material, (2,2-dimethyl-1,3-dioxolan-4-yl)methanol was prepared by step 2 of Example 1. Then, (2,2-dimethyl-1,3-dioxolan-4-yl)methanol and ( E )-3-(3,4-di(tert-butyldimethylsilyl)oxy)phenyl)acrylic acid was used as the raw material, and the title compound was prepared through steps 4-12 of Example 1. 1 H NMR (400MHz, CD3OD) δ 7.60 (d, J = 16.0 Hz, 1H), 7.12 (d, J = 2.0 Hz, 1H), 7.03 (dd, J =8.2, 2.1 Hz, 1H), 6.92 (d, J = 8.2 Hz, 1H), 6.31 (d, J = 16.0 Hz, 1H), 4.51 – 4.30 (m, 3H), 4.11 – 3.97 (m, 2H), 3.94 – 3.86 (m, 2H), 3.78 – 3.71 (m, 2H), 3.54 – 3.31 (m, 3H).

[0069] Example 6: (E)-3-(3,4-dihydroxyphenyl)-N-((S)-3-hydroxy-4-(β-D-glucoseoxy)butyl)acrylamide

[0070] Example 6 was prepared by synthesis method 2.

[0071] Step 1: S Preparation of 4-(2-azidoethyl)-2,2-dimethyl-1,3-dioxolane The ( S)-2-(2,2-dimethyl-1,3-dioxolan-4-yl)ethyl-1-ol (10.0 g, 68.4 mmol) and triphenylphosphine (23.3 g, 88.9 mmol) were dissolved in anhydrous tetrahydrofuran (100 mL), and diisopropyl azodicarboxylate (17.6 mL, 88.9 mmol) was slowly added dropwise at -5°C. After the addition was completed, the mixture was reacted at -5°C for 1 h. Then, trimethylsilyl azide (23.3 g, 88.9 mmol) was slowly added dropwise to the reaction system. After 1 h of reaction, the reaction was monitored by TLC. After the reaction was completed, tetrabutylammonium fluoride solution (27 mL, 27.3 mmol) and tetrahydrofuran were added. The liquids were separated, and the organic layer was concentrated under reduced pressure to obtain the intermediate, which was directly used in the next step.

[0072] Step 2: S Preparation of 4-azidobutyl-1,2-diol Dissolve the (S)-4-(2-azidoethyl)-2,2-dimethyl-1,3-dioxolane (4.0 g, 23.3 mmol) obtained in the previous step in acetic acid water (acetic acid: water = 4:1, 40 mL) and react at 60°C for 2 h. After the reaction is completed, dilute with dichloromethane, wash with saturated sodium bicarbonate, wash with water, and concentrate the dichloromethane layer under reduced pressure to obtain the product. 1 H NMR (400 MHz, CDCl3) δ3.67 (dd, J = 11.2, 3.2 Hz, 1H), 3.55 – 3.43 (m, 4H), 3.03 (q, J = 7.3 Hz, 1H),1.71 (q, J = 6.6 Hz, 2H). Step 3: S Preparation of 4-azido-1-((tert-butyldimethylsilyl)oxy)butyl-2-ol Dissolve the (S)-4-azidobutyl-1,2-diol (3.0 g, 22.8 mmol) and imidazole (2.0 g, 29.6 mmol) obtained in the previous step in dichloromethane, slowly add tert-butyldimethylsilyl chloride (4.5 g, 29.6 mmol) to the reaction bottle under ice bath, and stir at room temperature for 1 h. Dilute the reaction solution with dichloromethane, wash with water, and concentrate the dichloromethane layer under reduced pressure to obtain a crude product.

[0073] Step 4: S Preparation of 4-azido-2-((tert-butyldiphenylsilyl)oxy)-1-((tert-butyldimethylsilyl)oxy)butane The result of the previous step ( S)-4-azido-1-((tert-butyldimethylsilyl)oxy)butyl-2-ol (5.0 g, 20.2 mmol) and imidazole (2.7 g, 40.2 mmol) were dissolved in N,N -dimethylamide (50 mL), and slowly add tert-butyldiphenylsilyl chloride (7.1 g, 26.26 mmol) to the reaction bottle under ice bath. Then, react at 80 °C for 10 h. The reaction solution was diluted with ethyl acetate, washed with water, and the ethyl acetate layer was concentrated under reduced pressure to obtain a crude product, which was directly used in the next step.

[0074] Step 5: S Preparation of 4-azido-2-((tert-butyldiphenylsilyl)oxy)butyl-1-ol The result of the previous step ( S )-4-azido-2-((tert-butyldiphenylsilyl)oxy)-1-((tert-butyldimethylsilyl)oxy)butane (5.0 g, 10.3 mmol) was dissolved in tetrahydrofuran (50 mL), and 16% trifluoroacetic acid aqueous solution (40 mL, 80.3 mmol) was slowly added dropwise at 10°C, and the reaction was carried out at 10°C for 8 h. The reaction solution was diluted with ethyl acetate, washed with saturated sodium bicarbonate, and washed with water. The ethyl acetate layer was concentrated under reduced pressure and purified by column chromatography to obtain the target compound. 1 H NMR (400 MHz, CDCl3) δ 7.73– 7.63 (m, 4H), 7.51 – 7.34 (m, 6H), 3.92 – 3.87 (m, 1H), 3.58 – 3.42 (m,2H), 3.38 – 3.19 (m, 2H), 1.83 – 1.72 (m, 1H), 1.08 (s, 6H).

[0075] Step 6: S )-4-azido-2-((tert-butyldiphenylsilyl)oxy)-1-(2,3,4,6-tetrabenzoyl- β - D Preparation of -glucose oxy)butane The ( 2R,3R,4S,5R,6S )-2-((Benzoyloxy)methyl)-6-(2,2,2-trichloro-1-iminoethoxy)tetrahydro-2 H -pyran-3,4,5-benzoate (2.0 g, 2.7 mmol), obtained in the previous step ( S)-4-azido-2-((tert-butyldiphenylsilyl)oxy)butyl-1-ol (0.9 g, 2.3 mmol) and baked molecular sieves (2.5 g) were placed in a round-bottom flask, the gas was replaced three times, anhydrous dichloromethane (20 mL) was added, and the mixture was stirred for 3 h under nitrogen protection. Then trimethylsilyl trifluoromethanesulfonate (0.1 mL, 0.46 mmol) was added under ice bath, and the mixture was stirred at room temperature for 2 h. The mixture was quenched with saturated sodium bicarbonate aqueous solution, filtered, and the filtrate was diluted with dichloromethane, washed with water, and the organic layer was concentrated under reduced pressure to obtain the target intermediate. 1 H NMR (400MHz, CDCl3) δ 8.25 – 7.80 (m, 12H), 7.65 – 7.28 (m, 18H), 5.85 – 5.76 (m,1H), 5.67 (t, J = 9.7 Hz, 1H), 5.59 – 5.38 (m, 3H), 4.84 (d, J = 7.8 Hz, 1H), 4.57 – 4.26 (m, 4H), 3.75 (dd, J = 11.7, 2.4 Hz, 1H), 3.49 (dd, J = 11.6, 7.9 Hz,1H), 3.41 – 3.28 (m, 2H), 1.56 (s, 6H).

[0076] Step 7: S )-3-((tert-butyldiphenylsilyl)oxy)-4-(2,3,4,6-tetrabenzoyl- β - D Preparation of 1-glucoseoxy)butyl-1-amine The result of the previous step ( S )-4-azido-2-((tert-butyldiphenylsilyl)oxy)-1-(2,3,4,6-tetrabenzoyl-β-D-glucoseoxy)butane (0.2 g, 0.2 mmol), ammonium chloride (0.7 g) and zinc powder (0.6 g) were dissolved in methanol (1 mL) and water (1 mL) solution, stirred at room temperature for 2 h, filtered, and the filtrate was diluted with dichloromethane and washed with water. The organic layer was concentrated under reduced pressure to obtain the target intermediate.

[0077] Step 8: E )-3-(3,4-di(tert-butyldimethylsilyl)oxyphenyl)- N -(( S )-3-((tert-butyldiphenylsilyl)oxy)-4-(2,3,4,6-tetrabenzoyl- β - D -Glucose oxy)butyl)acrylamide The result of the previous step ( S )-3-((tert-butyldiphenylsilyl)oxy)-4-(2,3,4,6-tetrabenzoyl- β - D -glucoseoxy)butyl-1-amine (0.2 g, 0.2 mmol), ( E )-3-(3,4-di(tert-butyldimethylsilyl)oxy)phenyl)acrylic acid (0.1 g, 0.3 mmol) and O -(7-Azabenzotriazol-1-yl)- N,N,N,N -Tetramethyluronium hexafluorophosphate (0.2 g, 0.6 mmol) was dissolved in dichloromethane (2 mL) and stirred at room temperature for 8 h. The reaction solution was diluted with dichloromethane, washed with water, and the organic layer was concentrated under reduced pressure to obtain the target intermediate. 1 H NMR (400 MHz, CDCl3) δ 8.07 – 7.96 (m, 2H), 7.95 – 7.79 (m, 6H), 7.65 – 7.27 (m, 23H), 7.01 – 6.92 (m, 2H), 6.80 (d, J =8.8 Hz, 1H), 6.09 (d, J = 16.0 Hz, 1H), 5.81 (t, J = 9.6 Hz, 1H), 5.74 – 5.54 (m,2H), 5.42 (dd, J = 9.7, 7.8 Hz, 1H), 4.60 (dd, J = 12.1, 3.2 Hz, 1H), 4.48 – 4.38(m, 2H), 4.00 (ddd, J = 9.9, 5.1, 3.2 Hz, 1H), 3.88 – 3.77 (m, 2H), 3.47 – 3.14(m, 3H), 0.99 (d, J = 4.4 Hz, 18H), 0.95 (s, 9H), 0.21 (s, 6H), 0.16 (d, J = 4.3Hz, 6H).

[0078] Step 9: E )-3-(3,4-dihydroxyphenyl)- N -(( S )-3-hydroxy-4-(2,3,4,6-tetrabenzoyl- β - D-Glucose oxy)butyl)acrylamide The result of the previous step ( E )-3-(3,4-di(tert-butyldimethylsilyl)oxyphenyl)- N -(3-((tert-butyldiphenylsilyl)oxy)-4-(2,3,4,6-tetrabenzoyl- β - D -Glucoseoxy)butyl)acrylamide (0.1 g, 0.08 mmol) was dissolved in tetrahydrofuran (1 mL), and tetrabutylammonium fluoride solution (0.4 mL, 0.4 mmol) was added under ice bath, and the reaction was continued for 12 h. The reaction solution was quenched with saturated ammonium chloride solution, diluted with ethyl acetate, washed with water, and the ethyl acetate layer was concentrated under reduced pressure to obtain a crude product. The target compound was purified by column chromatography. 1 H NMR (400 MHz, CDCl3) δ 8.10 – 7.96 (m, 2H), 7.94 – 7.89(m, 4H), 7.83 – 7.80 (m, 2H), 7.63 – 7.26 (m, 13H), 7.10 (d, J = 1.9 Hz, 1H),6.88 (dd, J = 8.3, 1.9 Hz, 1H), 6.83 (d, J = 8.2 Hz, 1H), 6.13 (d, J = 16.0 Hz,1H), 5.91 (t, J = 9.7 Hz, 1H), 5.68 (t, J = 9.7 Hz, 1H), 5.51 (dd, J = 9.8, 7.8 Hz,1H), 4.87 (d, J = 7.8 Hz, 1H), 4.70 (dd, J = 12.2, 3.1 Hz, 1H), 4.46 (dd, J = 12.3,5.1 Hz, 1H), 4.28 – 4.02 (m, 2H), 3.81 (d, J = 8.0 Hz, 2H), 3.73 – 3.38 (m,3H), 3.22 (dd, J = 13.8, 6.0 Hz, 1H).

[0079] Step 10: E )-3-(3,4-dihydroxyphenyl)- N -(( S)-3-hydroxy-4-( β - D Preparation of -glucose oxy)butyl)acrylamide The result of the previous step ( E )-3-(3,4-dihydroxyphenyl)- N -(3-hydroxy-4-(2,3,4,6-tetrabenzoyl- β - D 2-Glucoseoxy)butyl)acrylamide (0.1 g, 0.1 mmol) was dissolved in methanol (10 mL), and lithium hydroxide methanol solution (10 mL, 0.05 M) was slowly added dropwise at -5°C. The reaction was allowed to proceed for 8 h, and then acidic resin (2 g) was added to quench the reaction. The reaction was diluted with water, washed with ethyl acetate and water, and the target compound was obtained by column chromatography. 1 H NMR (400 MHz, CDCl3) δ 7.97 (d, J = 16.0 Hz, 1H),7.72 (d, J = 1.9 Hz, 1H), 7.58 (dd, J = 8.3, 1.9 Hz, 1H), 7.13 (d, J = 8.2 Hz, 1H),6.72 (d, J = 16.0 Hz, 1H), 6.04 (t, J = 9.7 Hz, 1H), 5.96 (t, J = 9.7 Hz, 1H), 5.83(dd, J = 9.8, 7.8 Hz, 1H), 4.92 (d, J = 7.9 Hz, 1H), 4.78-4.66 (m, 1H), 4.54-4.37(m, 1H), 4.28 – 4.02 (m, 2H), 3.92 (d, J = 8.0 Hz, 2H), 3.73 – 3.38 (m, 3H), 3.22 (dd, J = 13.8, 6.0 Hz, 1H).

[0080] Example 7: S )-3-hydroxy-4-( β - D -Glucose oxy)butyl ( E )-3-(3,4-dimethoxyphenyl)acrylate

[0081] The same operation as in Example 4 was performed with ( E )-3-(3,4-dimethoxy)phenyl)acrylic acid instead of ( E )-3-(3,4-di(tert-butyldimethylsilyl)oxy)phenyl)acrylic acid to prepare the title compound. 1 H NMR (400 MHz, CD3OD) δ 7.67(d, J = 16.0 Hz, 1H), 7.16 (d, J = 2.0 Hz, 1H), 7.05 (dd, J = 8.0, 2.0 Hz, 1H),6.91 (d, J = 8.0 Hz, 1H), 6.37 (d, J = 16.0 Hz, 1H), 4.54 – 4.27 (m, 3H), 4.14 –4.03 (m, 2H), 3.88 (dd, J = 11.9, 1.5 Hz, 1H), 3.85 (S, 3H), 3.83 (S, 3H), 3.74– 3.61 (m, 2H), 3.52 – 3.50 (m, 1H), 3.31 – 3.23 (m, 2H), 2.00 – 1.88 (m,1H), 1.87 – 1.75 (m,1H).

[0082] Example 8: S )-3-hydroxy-4-( β - D -Glucose oxy)butyl cinnamate

[0083] The same operation as in Example 4 was performed, except that cinnamic acid was used instead of ( E )-3-(3,4-di(tert-butyldimethylsilyl)oxy)phenyl)acrylic acid to prepare the title compound. 1 H NMR (400 MHz, CD3OD) δ 7.73 (d, J = 16.0 Hz, 1H), 7.63-7.61 (m, 2H), 7.42-7.40 (m, 3H), 6.57 (d, J = 16.0 Hz, 1H), 4.61 – 4.33 (m,3H), 4.24 – 4.09 (m, 2H), 3.82 (dd, J= 11.9, 1.5 Hz, 1H), 3.69 – 3.64 (m,2H), 3.56 – 3.52 (m, 1H), 3.28 – 3.25 (m, 2H), 1.96 – 1.85 (m, 1H), 1.77 –1.65 (m, 1H).

[0084] Example 9: 2-Hydroxy-3-( β - D -Glucose oxy)propyl ( E )-3-(4-hydroxyphenyl)acrylate

[0085] The same operation as in Example 5 was performed, except that p-hydroxycinnamic acid was used instead of ( E )-3-(3,4-dihydroxy)phenyl)acrylic acid to prepare the title compound. 1 H NMR (400 MHz, CD3OD) δ 7.65 (d, J = 16.0 Hz, 1H), 7.61 (d, J = 8.0Hz, 1H), 681 ((d, J = 8.0 Hz, 1H), 6.35 (d, J = 16.0 Hz, 1H), 4.40 – 4.15 (m,3H), 4.12 – 4.05 (m, 1H), 4.02 – 3.95 (m, 1H), 3.88 (dd, J = 12.0, 1.7 Hz, 1H), 3.73 – 3.62 (m, 2H), 3.43 – 3.32 (m, 3H), 3.27 – 3.22 (m, 1H). Embodiment 10: S )-3-hydroxy-4-( β - D -Glucose oxy)butyl ( E )-3-(p-Tolyl)acrylate

[0086] The same operation as in Example 4 was performed, except that p-methylcinnamic acid was used instead of ( E )-3-(3,4-di(tert-butyldimethylsilyl)oxy)phenyl)acrylic acid to prepare the title compound. 1 H NMR (400 MHz, CD3OD) δ 7.71 (d, J= 16.0 Hz, 1H),7.59 (d, J = 8.0 Hz, 1H), 7.39 (d, J = 8.0 Hz, 1H), 6.42 (d, J = 16.0 Hz, 1H), 4.68– 4.35 (m, 3H), 4.26 – 4.12 (m, 2H), 3.84 (dd, J = 11.9, 1.5 Hz, 1H), 3.71 –3.66 (m, 2H), 3.52 – 3.49 (m, 1H), 3.26 – 3.21 (m, 2H), 2.41 (s, 3H), 1.96 –1.85 (m, 1H), 1.77 – 1.65 (m, 1H).

[0087] Example 11: S )-3-hydroxy-4-(β-D-glucoseoxy)butyl( E )-3-(4-Chlorophenyl) acrylate

[0088] The same operation as in Example 4 was performed, except that p-chlorocinnamic acid was used instead of ( E )-3-(3,4-di(tert-butyldimethylsilyl)oxy)phenyl)acrylic acid to prepare the title compound. 1 H NMR (400 MHz, CD3OD) δ 7.71 (d, J = 16.0 Hz, 1H),7.62 (d, J = 8.0 Hz, 1H), 7.68 (d, J = 8.0 Hz, 1H), 6.46 (d, J = 16.0 Hz, 1H), 4.71– 4.46 (m, 3H), 4.31 – 4.17 (m, 2H), 3.86 – 3.78 (m, 1H) , 3.69 – 3.64 (m,2H), 3.56 – 3.50 (m, 1H), 3.28 – 3.23 (m, 2H), 2.02 – 1.95 (m, 1H), 1.76 –1.63 (m, 1H).

[0089] Example 12: S )-3-hydroxy-4-(2,3,4,6-tetramethoxy- β - D-Glucose oxy)butyl ( E )-3-(3,4-dimethoxyphenyl)acrylate

[0090] The title compound was prepared by the same procedure as in Example 4, substituting 2,3,4,6-tetramethylglucose for 2,3,4,6-tetrabenzoylglucose. 1 H NMR (400 MHz, CD3OD) δ 7.69 (d, J = 16.0 Hz, 1H), 7.16 (d, J =2.0 Hz, 1H), 7.10 (dd, J = 8.0, 2.0 Hz, 1H), 6.90 (d, J = 8.0 Hz, 1H), 6.36 (d, J =16.0 Hz, 1H), 4.58 – 4.29 (m, 3H), 4.11 – 4.03 (m, 2H), 3.89 (dd, J = 11.9, 1.5Hz, 1H), 3.85 (s, 3H), 3.83 (s, 3H), 3.74 – 3.61 (m, 2H), 3.56 (s, 9H), 3.52– 3.50 (m, 1H), 3.46 (S, 3H), 3.31 – 3.23 (m, 2H), 2.00 – 1.88 (m, 1H), 1.88 – 1.79 (m, 1H).

[0091] Example 13: S )-3-hydroxy-4-(2,3,4,6-tetrabenzoyl- β - D -Glucose oxy)butyl ( E )-3-(3,4-dihydroxyphenyl)acrylate

[0092] The title compound was prepared by the same procedure as described in Example 4. 1 H NMR (400 MHz, CDCl3) δ 8.06 – 7.78(m, 8H), 7.60 – 7.26 (m, 13H), 7.13 (d, J = 1.9 Hz, 1H), 6.97 (dd, J = 8.4, 1.9Hz, 1H), 6.88 (d, J= 8.2 Hz, 1H), 6.18 (d, J = 15.9 Hz, 1H), 5.94 (t, J = 9.7 Hz,1H), 5.72 (t, J = 9.7 Hz, 1H), 5.56 (dd, J = 9.8, 7.8 Hz, 1H), 4.92 (d, J = 7.9 Hz,1H), 4.70 (dd, J = 12.1, 3.3 Hz, 1H), 4.50 (dd, J = 12.2, 4.9 Hz, 1H), 4.30 –4.16 (m, 3H), 3.99 (dd, J = 10.3, 2.9 Hz, 1H), 3.59 (dd, J = 10.3, 6.8 Hz, 1H),1.78 (dt, J = 12.2, 6.6 Hz, 2H).

[0093] Example 14: 3-tert-hydroxy-2-methenyl-4-(2,3,4,6-tetraacetoxy- β - D -Glucose oxy)butyl ( E )-3-(3,4-dihydroxyphenyl)acrylate

[0094] The title compound was prepared by the same procedure as described in Example 1. 1 H NMR (400 MHz, CDCl3) δ 7.71 (d, J =16.0 Hz, 1H), 7.21 (d, J = 2.0 Hz, 1H), 7.06 (dd, J = 8.0, 2.0 Hz, 1H), 6.98 (d, J = 8.0 Hz, 1H), 6.49 (d, J = 16.0 Hz, 1H), 5.51 (s, 1H), 5.34 (s, 1H), 4.92 –4.84 (m, 2H), 4.53 – 4.51 (m, 1H), 4.42 (dd, J= 7.7, 3.1 Hz, 1H), 4.38 – 3.54(m, 4H), 3.29 – 3.20 (m, 4H), 2.07 – 2.00 (m, 12H). Embodiment 15: N -3-( β - D -Glucose oxy)propyl ( E )-3-(3,4-dihydroxyphenyl)acrylamide

[0095] The title compound was prepared by the same procedure as described in Example 6. 1 H NMR (400 MHz, CD3OD) δ 7.51 (d, J =16.0 Hz, 1H), 7.12 (d, J = 2.0 Hz, 1H), 6.99 (dd, J = 8.2, 2.1 Hz, 1H), 6.83 (d, J = 8.1 Hz, 1H), 6.42 (d, J = 16.0 Hz, 1H), 5.81 (d, J = 5.2 Hz, 1H), 5.21 (t, J =2.8 Hz, 1H), 4.41 – 4.38 (m, 1H), 4.20 (d, J = 4.2 Hz, 2H), 4.04 – 3.94 (m,1H), 3.61 – 3.51 (m, 2H), 3.41 – 3.32 (m, 3H), 1.73 – 1.66 (m, 2H). Embodiment 16: N -4-( β - D -Glucose oxy)butyl ( E )-3-(3,4-dihydroxyphenyl)acrylamide

[0096] The title compound was prepared by the same procedure as described in Example 6. 1 H NMR (400 MHz, CD3OD) δ 7.38 (d, J =16.0 Hz, 1H), 7.00 (d, J = 2.0 Hz, 1H), 6.90 (dd, J= 8.2, 2.1 Hz, 1H), 6.76 (d, J = 8.1 Hz, 1H), 6.36 (d, J = 16.0 Hz, 1H), 5.72 (d, J = 5.2 Hz, 1H), 5.12 (t, J =2.8 Hz, 1H), 4.39 – 4.37 (m, 1H), 4.17 (d, J = 4.2 Hz, 2H), 3.98 – 3.94 (m,1H), 3.53 – 3.49 (m, 2H), 3.35 – 3.28 (m, 3H), 1.68 – 1.59 (m, 4H). Example 17: R )-2-methyl-4-( β - D -Glucose oxy)propyl ( E )-3-(3,4-dihydroxyphenyl)acrylate

[0097] The title compound was prepared by the same procedure as described in Example 1. 1 H NMR (400 MHz, CD3OD) δ 7.71 (d, J =16.0 Hz, 1H), 7.23 (d, J = 2.0 Hz, 1H), 7.02 (dd, J = 8.2, 2.1 Hz, 1H), 6.93 (d, J = 8.1 Hz, 1H), 6.48 (d, J = 16.0 Hz, 1H), 5.31 – 5.26 (m, 1H), 5.16 (d, J = 7.6Hz, 1H), 4.51 – 4.42 (m, 1H), 4.33 – 4.22 (m, 2H), 4.14 – 3.94 (m, 2H), 3.71 – 3.62 (m, 2H), 3.41 – 3.32 (m, 3H), 2.05 (s, 3H).

[0098] Example 18: E )-2-methyl-4-( β - D -glucoseoxy)but-2-en-1-yl( E)-3-(3,4-dihydroxyphenyl)acrylate

[0099] The title compound was prepared by the same procedure as described in Example 1. 1 H NMR (400 MHz, CD3OD) δ 7.83 (d, J =16.0 Hz, 1H), 7.33 (s, 1H), 7.22 (dd, J = 8.0 Hz, 1H), 7.06 (d, J = 8.0 Hz, 1H),6.55 (d, J = 16.0 Hz, 1H), 5.97 (s, 1H), 4.73 – 4.70 (m, 2H), 4.59 – 4.57 (m,2H), 4.17– 4.14 (m, 1H), 3.39 – 3.35 (m, 2H), 3.65 – 3.46 (m, 4H), 2.80 (s,3H).

[0100] Example 19: S )-3-hydroxy-4-( β - D -Glucose oxy)butyl 3-(3,4-dihydroxyphenyl) propionate

[0101] The title compound was prepared by the same procedure as described in Example 4. 1 H NMR (400 MHz, CD3OD) δ 7.13 (d, J =1.9 Hz, 1H), 6.97 (dd, J = 8.4, 1.9 Hz, 1H), 6.88 (d, J = 8.2 Hz, 1H), 5.99 (t, J =9.6 Hz, 1H), 5.78 (t, J = 9.7 Hz, 1H), 5.63 (dd, J = 9.8, 7.8 Hz, 1H), 4.97 (d, J =7.9 Hz, 1H), 4.74 (dd, J = 12.1, 3.3 Hz, 1H), 4.59 (dd, J= 12.2, 4.9 Hz, 1H), 4.35 – 4.02 (m, 2H), 4.03 – 3.78 (m, 1H), 3.63 (dd, J = 9.8, 5.7 Hz, 1H), 3.06(q, J = 7.8 Hz, 2H), 2.77 – 2.55 (m, 2H), 1.97 – 1.59 (m, 4H).

[0102] Example 20: S )-3-hydroxy-4-( β - D -Glucose oxy)butyl benzoate

[0103] The title compound was prepared by the same procedure as described in Example 4. 1 H NMR (400 MHz, CD3OD) δ 7.63-7.61(m, 2H), 7.42-7.40 (m, 3H), 4.43 – 4.18 (m, 3H), 4.05 – 3.93 (m, 2H), 3.88(dd, J = 11.9, 1.5 Hz, 1H), 3.76 – 3.62 (m, 2H), 3.54 – 3.49 (m, 1H), 3.31 –3.23 (m, 2H), 2.00 – 1.88 (m, 1H), 1.87 – 1.75 (m, 1H).

[0104] Example 21: S )-3-hydroxy-4-( β - D -fucosyl)butyl( E )-3-(3,4-dihydroxyphenyl)acrylate

[0105] by( S )-1,2,4-butanetriol and fucose were used as raw materials and the title compound was prepared by the same operation as described in Example 4. 1 HNMR (400 MHz, CD3OD) δ 7.54 (d, J = 16.0 Hz, 1H), 7.06 (d, J = 2.0 Hz, 1H), 6.95(dd, J = 8.2, 2.1 Hz, 1H), 6.80 (d,J = 8.2 Hz, 1H), 6.26 (d, J = 16.0 Hz, 1H), 4.43 – 4.18 (m, 3H), 4.05 – 3.93 (m, 2H), 3.91 (d, J = 5.2 Hz, 1H), 3.65 – 3.623.50 (m, 3H), 3.31 – 3.23 (m, 1H), 2.00 – 1.88 (m, 1H), 1.87 – 1.75 (m, 1H), 1.27 (d, J = 6.0 Hz, 3H).

[0106] Example 22: S )-3-hydroxy-4-(2,3,4,6-tetraacetoxy- β - D -mannoseoxy)butyl( E )-3-(3,4-dihydroxyphenyl)acrylate

[0107] The title compound was prepared by the same procedure as described in Example 4. 1 H NMR (400 MHz, CD3OD) δ 7.62 (d, J =16.0 Hz, 1H), 7.10 (d, J = 2.0 Hz, 1H), 7.01 (dd, J = 8.1, 2.0 Hz, 1H), 6.91 (d, J = 8.1 Hz, 1H), 6.29 (d, J = 16.0 Hz, 1H), 4.43 – 4.37 (m, 2H), 4.30 – 4.27 (m,2H), 4.13 – 4.10 (m, 2H), 3.86 – 3.83 (m, 1H), 3.65 – 3.62 3.50 (m, 3H), 3.31– 3.23 (m, 2H), 2.17 – 1.99 (m, 12H), 1.96 – 1.88 (m, 1H), 1.87 – 1.75 (m,1H).

[0108] Example 23: Anti-UC activity detection of compounds according to the present invention: 1. Anti-UC activity at the cellular level (1) Anti-UC activity in LPS-induced activated RAW264.7 macrophage model: The experiment set up a normal control group, LPS model group, different drug intervention groups, and dexamethasone group, with 3 replicates in each group. DMEM complete medium and RAW264.7 macrophage cell lines that were cultured normally for 24 hours were taken, and the cells were pretreated with different drugs at different concentrations for 1 hour, and then LPS with a final concentration of 1 μg / ml was added to stimulate the cells for 24 hours. The supernatant was taken and the NO (nitric oxide is one of the inflammatory mediators and can feedback the level of inflammation to a certain extent) was measured by Griess kit method (Thermo Fisher), and the inflammatory factors TNF-α, IL-1β, IL-6, and PGE2 were measured by ELISA method. As described in Example 1, the compound (PBA) can effectively inhibit the production of LPS-induced inflammatory factors and chemokines including TNF-α, IL-6, CXCL10, IL-1β and iNOS. For example, at a concentration of 10 μM, the compound described in Example 1 has a better effect on reducing the expression of inflammatory factors TNFα mRNA, IL-6 mRNA, CXCL10, IL-1β mRNA and iNOS mRNA than the non-steroidal anti-inflammatory drug dexamethasone (DEX). The compound described in Example 1 reduces the expression level of inflammatory factor TNFα mRNA from 40.2 to 1.3 (9.2 for dexamethasone); reduces the expression level of IL-6 mRNA from 37.3 to 1.6 (9.8 for dexamethasone); reduces the expression level of CXCL10 from 44.6 to 1.2 (10.0 for dexamethasone); reduces the expression level of IL-1β mRNA from 12.7 to 0.8 (3.9 for dexamethasone); reduces the expression level of iNOS mRNA from 23.6 to 1.1 (9.9 for dexamethasone) ( Figure 1 ).

[0109] (2) Anti-UC activity in TNF-ɑ-induced human normal colon epithelial NCM460 cell model: The experiment set up a normal control group, a TNF-ɑ model group, different drug intervention groups, and a dexamethasone group, with 3 replicates in each group. DMEM complete medium and colon epithelial NCM460 cell lines that were cultured normally for 24 hours were taken, and the cells were pretreated with different drugs at different concentrations for 1 hour, and then TNF-ɑ with a final concentration of 50 ng / ml was added to stimulate the cells for 24 hours. ELISA method was used to measure TNF-α, IL-1β and IL-6. As described in Example 1, the compound (PBA) can effectively inhibit the production of inflammatory factors IL-6 and IL-1β induced by TNF-α (at 20 μM, the expression level of IL-1β mRNA was downregulated from 26.3 to 5.8; the expression level of IL-6 mRNA was downregulated from 9.4 to 6.1). At the same time, at a concentration of 5-80 μM, the compound described in Example 1 did not have a significant effect on cell viability, proving that it had no obvious toxicity ( Figure 2 ).

[0110] 2. Anti-UC activity in animals (1) Anti-UC activity in the DSS-induced mouse ulcerative colitis model: 3% (m / v) dextran sulphate sodium (DSS) solution was prepared with sterile water. SPF-grade 6-8-week-old male C57BL / 6N mice were randomly divided into a normal control group, a model control group, a positive drug group (mesalazine), and different drug groups, with 10 mice in each group. The mice were allowed to drink 3% (m / v) DSS solution freely for 10 consecutive days. The weight, stool morphology, and blood in the stool of the mice were observed and recorded every day. The disease activity index (DAI) was used to combine the percentage of weight loss, stool viscosity, and stool bleeding of the mice for comprehensive scoring. During the experiment, the mice after modeling had different degrees of diarrhea, blood in the stool, and redness and swelling of the anus. When the experiment reached the 10th day, the drinking water of each group of mice was replaced with fresh sterile water and the mice were dissected on the 11th day. After the experiment, the colon length and colon tissue of each group of mice were stained with HE, and the success of the model was judged based on the weight changes and DAI scores of each group of mice during the experiment. Figure 3The results show that the compounds described in the present invention, such as the compounds described in Examples 1, 4, 5 and 9, can effectively slow down the weight loss of mice with ulcerative colitis, reduce the disease activity index (DAI) of mice (the DAI index of the model group on the 10th day was 3.13, the P1 group was 3.10, the P2 group was 1.94, the P3 group was 1.94, the P4 group was 2.46, the PBA group was 1.92, and the mesalazine group was 2.05), and improve the symptoms of colorectal stenosis and shortening caused by ulcerative colitis (the average colon length of the model group was 6.43 cm, the P1 group was 6.50 cm, the P2 group was 9.92 cm, the P3 group was 6.64 cm, the P4 group was 7.13 cm, the PBA group was 7.72 cm, and the mesalazine group was 7.81 cm).

[0111] Figure 4 The curves of different doses of the compound of Example 1 inhibiting DSS-induced weight loss in mice. Figure 4 It can be seen that the body weight of mice in the model group (DSS group) decreased significantly to 72.0% over time. In comparison, after administration (the compound described in Example 1 and mesalazine), the weight loss trend of mice was significantly slowed down, and the compound described in Example 1 reduced the weight of mice in a dose-dependent manner. On the 10th day, the average body weight of the 10 mg / kg compound described in Example 1 and 40 mg / kg mesalazine treatment groups was 89.5%.

[0112] Figure 5 The curves showing the inhibition of the increase of DAI in mice by the compound of Example 1 at different doses are shown. Figure 5 It can be seen that the disease activity index of mice in the model group (DSS group) increased significantly over time to 3.58. After administration (the compound described in Example 1 and mesalazine), the downward trend of the disease activity index was significantly slowed down, and the compound described in Example 1 slowed down the increase of the disease activity index of mice in a dose-dependent manner. Among them, 10 mg / kg of the compound described in Example 1 can produce an therapeutic effect equivalent to 40 mg / kg of mesalazine (DAI indexes are 2.3 and 2.2, respectively).

[0113] Figure 6 The results show that different doses of the compound of Example 1 inhibited the shortening and narrowing of the mouse colon. Figure 6It can be seen that the colon length (5.55 cm) of the mice in the model group (DSS group) was significantly shorter than that of the normal group (8.34 cm). After administration of the compound described in Example 1 (2.5 mg / kg, 5 mg / kg, 10 mg / kg), the length of the mice's colon was significantly reduced, and the lengths were 6.14, 6.65, and 6.97 cm, respectively. Among them, the therapeutic effect of 10 mg / kg of the compound described in Example 1 was equivalent to 40 mg / kg of mesalazine (the colon lengths were 6.97 cm vs 6.94 cm, respectively).

[0114] Figure 7 The expression of inflammatory factors TNF-α, IL-6, and IL-1β mRNA in mice and the levels of TNF-α, IL-6, and IL-1β in peripheral blood of mice during treatment with different doses of the compound of Example 1 are shown. Figure 7 It can be seen that the expression genes of inflammatory factors and the expression of inflammatory factors in peripheral blood in the model group (DSS group) were significantly increased. After the administration of the compound described in Example 1 and mesalazine, the expression of inflammatory factor genes and the content of inflammatory factors in peripheral blood were significantly decreased. Among them, in the IL-6 group, the therapeutic effect of 10 mg / kg of the compound described in Example 1 was better than 40 mg / kg of mesalazine, and the therapeutic effect of 10 mg / kg of the compound described in Example 1 in the TNF-α group and IL-1β group was equivalent to 40 mg / kg of mesalazine, and the compound described in Example 1 inhibited the expression of inflammatory factors in a dose-dependent manner.

[0115] Figure 8 The results of colon HE staining during treatment with different doses of the compound of Example 1 are shown. The results show that after low, medium and high doses of the compound of Example 1, intestinal mucosal ulcers were reduced, inflammatory cell infiltration was alleviated, and glandular arrangement tended to be normal, and the effect was dose-dependent, and the high-dose group had the most significant effect.

[0116] Example 24: Targeting study of compounds of the present invention Wild-type C57BL6 mice and Keap1 conditional knockout mice (purchased from the Southern Animal Center) were grouped, modeled, and given corresponding compounds and positive drugs according to the above UC model. After the experiment, the weight change, disease activity index (DAI) score, and colon length of the mice were measured.

[0117] Fig. 9It shows that after knocking out Keap1, the therapeutic effect of the compound in Example 1 is reduced. The results show that for wild-type mice, the compound in Example 1 has a significant inhibitory effect on the weight loss of mice (the average weight of the WT+DSS group decreased to 73%; the weight of the WT+PBA10mg / kg group decreased to 86%). For Keap1 knockout mice, the inhibitory effect of the compound in Example 1 on the weight loss of mice is reduced (the average weight of the Keap1- / - +DSS group decreased to 71%; the average weight of the Keap1- / - +PBA10mg / kg group decreased to 76%). Compared with the wild-type group, the weight loss inhibition rate of the compound in Example 1 on the Keap1 knockout mice was significantly reduced (the weight of the WT+PBA10mg / kg group decreased to 86%; the average weight of the Keap1- / - +PBA10mg / kg group decreased to 76%). Similar to the results of body weight changes, for wild-type mice, the compound described in Example 1 can effectively inhibit the increase of the DAI index of mice (the DAI index of the WT+DSS group is 3.41; the DAI index of the WT+PBA10mg / kg group is 2.23). For Keap1 knockout mice, the inhibitory effect of the compound described in Example 1 on the increase of the DAI index of mice was significantly reduced (the DAI index of the Keap1- / - +DSS group is 3.46; the DAI index of the Keap1- / - +PBA10mg / kg group is 3.08). Compared with the wild-type group, the inhibitory effect of the compound described in Example 1 on the increase of the DAI index of Keap1 knockout mice was significantly reduced (the DAI index of the WT+PBA10mg / kg group is 2.23; the DAI index of the Keap1- / - +PBA10mg / kg group is 3.08). In addition, for wild-type mice, the compound described in Example 1 can effectively inhibit the shortening of the mouse colon (the colon length of the WT+DSS group is 4.9 cm; the colon length of the WT+PBA10mg / kg group is 6.2 cm). For Keap1 knockout mice, the inhibitory effect of the compound described in Example 1 on the shortening of the mouse colon is significantly reduced (the colon length of the Keap1- / - +DSS group is 4.6 cm; the DAI index of the Keap1- / - +PBA10mg / kg group is 4.8 cm). Compared with the wild-type group, the inhibitory effect of the compound described in Example 1 on the shortening of the colon of Keap1 knockout mice is significantly reduced (the colon length of the WT+PBA10mg / kg group is 6.2 cm; the colon length of the Keap1- / - +PBA10mg / kg group is 4.8 cm). The above results show that the compounds of the present invention represented by Example 1 are mainly effective by targeting Keap1.

Claims

1. A glycoside compound targeting Keap1, characterized in that: The compound has the structural formula (I), (I), in: The aromatic ring (Ar) is a benzene ring, a naphthalene ring, an anthracene ring or an aromatic heterocyclic ring containing N, O and S, and the aromatic ring has a substituent R1 or has no substituent. m is 0, 1 or 2; X is O or NH; Y is selected from linear or branched alkyl, alkenyl and alkynyl groups containing 1 to 8 carbon atoms, wherein the substituents on the chain can be independently selected from halogen, hydroxyl, amino, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, C 1-6 Alkylthio or any combination of these functional groups; W is a glycosyl group.

2. The glycoside compound targeting Keap1 according to claim 1, characterized in that The substituent R1 includes the following functional groups or any combination thereof: halogen, hydroxyl, cyano, nitro, amino, ester, amide, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, C 1-6 Haloalkyl, C 1-6 Alkylthio.

3. The glycoside compound targeting Keap1 according to claim 1, characterized in that The sugar group is a mono-substituted or poly-substituted five-membered or six-membered monosaccharide or polysaccharide.

4. The glycoside compound targeting Keap1 according to claim 3, characterized in that: The glycosyl group includes the following monosaccharides or any combination thereof: glucose, mannose, rhamnose, fucose, ribose, galactose, arabinose and uronic acid.

5. The glycoside compound targeting Keap1 according to claim 4, characterized in that: The substituents of the saccharide group include the following groups or any combination thereof: methyl, ethyl, benzoyl, tert-butyldimethylsilyl, tert-butyldiphenylsilyl, p-methoxybenzyl, benzyl and o-dibenzoyl.

6. The glycoside compound targeting Keap1 according to claim 5, characterized in that The glycoside compound targeting Keap1 is a compound having the following structural formula: (1) ( S )-3-hydroxy-2-methenyl-4-( β - D -Glucose oxy)butyl ( E )-3-(3,4-hydroxyphenyl)acrylate, ; (2) 3-Hydroxy-2-methenyl-4-( β - D -Glucose oxy)butyl ( E )-3-(3,4-dihydroxyphenyl)acrylate, ; (3) ( S )-4-hydroxy-2-methenyl-3-( β - D -Glucose oxy)butyl ( E )-3-(3,4-dihydroxyphenyl)acrylate, ; (4) ( S )-3-hydroxy-4-( β - D -Glucose oxy)butyl ( E )-3-(3,4-dihydroxyphenyl)acrylate, ; (5) 2-Hydroxy-3-( β - D -Glucose oxy)propyl ( E )-3-(3,4-dihydroxyphenyl)acrylate, ; (6) ( E )-3-(3,4-dihydroxyphenyl)- N -(( S )-3-hydroxy-4-( β - D -glucoseoxy)butyl)acrylamide, ; (7) ( S )-3-hydroxy-4-( β - D -Glucose oxy)butyl ( E )-3-(3,4-dimethoxyphenyl)acrylate, ; (8) ( S )-3-hydroxy-4-( β - D -Glucose oxy)butyl cinnamate, ; (9) 2-Hydroxy-3-( β - D -Glucose oxy)propyl ( E )-3-(4-hydroxyphenyl)acrylate, ; (10) ( S )-3-hydroxy-4-( β - D -Glucose oxy)butyl ( E )-3-(p-methylphenyl)acrylate, ; (11) ( S )-3-hydroxy-4-( β - D -Glucose oxy)butyl ( E )-3-(4-chlorophenyl) acrylate, ; (12) ( S )-3-hydroxy-4-(2,3,4,6-tetramethoxy- β - D -Glucose oxy)butyl ( E )-3-(3,4-dimethoxyphenyl)acrylate, ; (13) ( S )-3-hydroxy-4-(2,3,4,6-tetrabenzoyl- β - D -Glucose oxy)butyl ( E )-3-(3,4-dihydroxyphenyl)acrylate, ; (14) 3-Hydroxy-2-methenyl-4-(2,3,4,6-tetraacetoxy- β - D -Glucose oxy)butyl ( E )-3-(3,4-dihydroxyphenyl)acrylate, ; (15) N -3-( β - D -Glucose oxy)propyl ( E )-3-(3,4-dihydroxyphenyl)acrylamide, ; (16) N -4-( β - D -Glucose oxy)butyl ( E )-3-(3,4-dihydroxyphenyl)acrylamide, ; (17) ( R )-2-methyl-4-( β-D -Glucose oxy)propyl ( E )-3-(3,4-dihydroxyphenyl)acrylate, ; (18) ( E )-2-methyl-4-( β - D -glucoseoxy)but-2-en-1-yl( E )-3-(3,4-dihydroxyphenyl)acrylate, ; (19) ( S )-3-hydroxy-4-( β - D -glucoseoxy)butyl 3-(3,4-dihydroxyphenyl)propionate, ; (20) ( S )-3-hydroxy-4-( β - D -Glucose oxy)butyl benzoate, ; (twenty one) ( S )-3-hydroxy-4-( β - D -fucosyl)butyl( E )-3-(3,4-dihydroxyphenyl)acrylate, ;or (twenty two) ( S )-3-hydroxy-4-(2,3,4,6-tetraacetoxy- β - D -mannoseoxy)butyl( E )-3-(3,4-dihydroxyphenyl)acrylate 。 7. The racemate, optical isomer and / or tautomer compound of the Keap1-targeting glycoside compound according to any one of claim 6. 8 . The pharmaceutically acceptable salt, pharmaceutically acceptable ester, amide derivative, or pharmaceutically acceptable solvate thereof of the glycoside compound targeting Keap1 according to claim 6 .

9. The method for preparing a glycoside compound targeting Keap1 according to any one of claims 1 to 6, characterized in that: The method comprises the following steps: (1) condensing a substituted aromatic acid with a polyhydroxyalkyl chain to prepare a substituted aromatic acid ester or amide, , wherein R1, m, X and Y are as defined in the compound of general formula (I) in claim 1, R2 is a protective group for hydroxyl, including the following functional groups: acetyl, benzyl, p-methoxybenzyl, methoxymethyl, allyl, tert-butyldimethylsilyl, tert-butylsilyl, benzyloxycarbonyl, phthaloyl, trityl and methoxycarbonyl; (2) Removal of the protective group R from the hydroxyl group of the substituted aromatic ester or amide intermediate 2, ; (3) the substituted aromatic acid ester or amide after removal of the hydroxyl protecting group undergoes a glycosidation reaction with a glycosyl donor to obtain a compound of the general formula (I), , Among them, R3 is alkylthio, arylthio, trichloroacetonitrile and acetoxy.

10. The method for preparing the glycoside compound targeting Keap1 according to any one of claims 1 to 6, characterized in that: The method comprises the following steps: (1) A polyhydroxyalkyl chain is reacted with a glycosyl donor to produce an alkyl glycoside. , wherein X, Y and W are as defined in the compound of general formula I in claim (1); R3 is an alkylthio group, an arylthio group, a trichloroacetonitrile group and an acetoxy group; R4 is a protective group for a hydroxyl group or an amino group, including the following functional groups: acetyl, benzyl, p-methoxybenzyl, methoxymethyl, allyl, tert-butyldimethylsilyl, tert-butylsilyl, benzyloxycarbonyl, phthaloyl, trityl and t-methoxycarbonyl; (2) removing the hydroxyl or amino protecting group R4 from the alkyl glycoside intermediate under appropriate conditions, ; (3) the alkyl glycoside after removing the protecting group R4 on X undergoes a condensation reaction with a substituted aryl acid ester to obtain a compound of the general formula (I), , wherein R1 is the same as defined in the compound of general formula (I) in claim 1.

11. Use of the glycoside compound targeting Keap1 according to any one of claims 1 to 6, its racemate, optical isomer and / or tautomer, or its pharmaceutically acceptable salt, pharmaceutically acceptable ester, amide derivative, or pharmaceutically acceptable solvate in the preparation of a therapeutic drug for diseases caused by abnormal activity of Kelch-like ECH-associated protein 1.

12. The use according to claim 11, characterized in that: The disease caused by abnormal activity of Kelch-like ECH associated protein 1 is ulcerative colitis.